Boldes Tomer, Shehadeh Rabie, Shavit Eitan, Kassem Firas, Nageris Benny, Sowerby Leigh J, Biadsee Ameen
Department of Otolaryngology-Head and Neck Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.
School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
J Clin Med. 2025 Mar 29;14(7):2347. doi: 10.3390/jcm14072347.
Designed to measure symptoms and quality-of-life impacts, the chronic rhinosinusitis patient-reported outcome (CRS-PRO) questionnaire is a novel instrument tailored to CRS patients. This study aimed to translate the CRS-PRO into Hebrew, adapt it cross-culturally, and assess its reliability and validity. A prospective study was conducted with 127 participants across three groups: CRS, functional endoscopic sinus surgery (FESS), and control groups (healthy individuals). Participants completed the Hebrew CRS-PRO at baseline and one month later. The Hebrew version was developed according to the International Society for Pharmacoeconomics and Outcomes Research guidelines for translation and cross-cultural adaptation. Of the 127 participants (mean age 47.3 ± 17.7 years, range 18-93), 77 were males (60.6%), and 50 were females (39.4%). The Hebrew CRS-PRO demonstrated high internal consistency (Cronbach's alpha 0.936) and strong discriminant validity among the three groups. Baseline mean scores were 7.2 for the control group, 25.2 for the FESS group, and 27.1 for the CRS group, which subsequently decreased to 6.5, 12.9, and 20.4, respectively, after one month (ANOVA, < 0.001). Test-retest reliability, supported by Pearson's correlation ( < 0.01) and intraclass correlation ( < 0.0001), demonstrated the questionnaire's effectiveness in identifying CRS-related symptoms and monitoring improvement after FESS. The adaptation and validation of the CRS-PRO into Hebrew resulted in a reliable instrument in patients with CRS. It exhibited robust reliability, internal consistency, and strong discriminant validity, effectively differentiating between healthy individuals and CRS patients and those who are pre- and post-FESS. Additionally, the Hebrew CRS-PRO questionnaire may be effective for evaluating patients before and after FESS surgery.
慢性鼻-鼻窦炎患者报告结局（CRS-PRO）问卷旨在测量症状及对生活质量的影响，是一种专为CRS患者量身定制的新型工具。本研究旨在将CRS-PRO翻译成希伯来语，进行跨文化改编，并评估其信度和效度。对127名参与者进行了一项前瞻性研究，分为三组：CRS组、功能性鼻内镜鼻窦手术（FESS）组和对照组（健康个体）。参与者在基线时和1个月后完成希伯来语CRS-PRO问卷。希伯来语版本是根据国际药物经济学和结局研究协会的翻译和跨文化改编指南制定的。127名参与者（平均年龄47.3±17.7岁，范围18 - 93岁）中，77名男性（60.6%），50名女性（39.4%）。希伯来语CRS-PRO显示出较高的内部一致性（Cronbach's α 0.936），且在三组之间具有较强的区分效度。对照组基线平均得分为7.2，FESS组为25.2，CRS组为27.1，1个月后分别降至6.5、12.9和20.4（方差分析，<0.001）。重测信度经Pearson相关性分析（<0.01）和组内相关性分析（<0.0001）支持，表明该问卷在识别CRS相关症状及监测FESS术后改善情况方面有效。CRS-PRO翻译成希伯来语并进行验证后，成为一种适用于CRS患者的可靠工具。它具有强大的信度、内部一致性和较强的区分效度，能有效区分健康个体与CRS患者以及FESS术前和术后患者。此外，希伯来语CRS-PRO问卷可能对评估FESS手术前后的患者有效。
